Back to search results

ADAPT Forward: Evaluating Treatments for Myasthenia Gravis

The ADAPT Forward study is looking at how safe and effective different treatments are for people with myasthenia gravis (MG), including generalized myasthenia gravis (gMG). This study aims to find the best ways to reduce side effects and improve your quality of life. We are testing treatments like efgartigimod IV and empasiprubart IV. To join, you must be at least 18 years old and have a diagnosis of MG. The main goal is to understand the safety and tolerability of these treatments over a period of up to approximately 7 years. The current status of this study is unclear, and we plan to enroll about 70 participants.

Study design
This is an observational platform study, meaning it's designed to evaluate multiple treatments under one main plan. It involves different sub-studies, each looking at a specific treatment approach.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
You would be followed for safety for a period of variable duration, which could be up to approximately 7 years depending on the specific treatment sub-study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07294170

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Recruiting
Not specifiedAges 18+Observational
argenx
~70 participants
Updated 2026-08-21 on ClinicalTrials.gov
What's tested:Efgartigimod IVEmpasiprubart IVPlacebo IVEfgartigimod PH20 SC PFS

At a glance

Recruiting sites
30 of 30 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To determine the safety and tolerability of multiple regimens (monotherapy or add-on therapy to backbone therapy) in MG subtypes
Measured over Up to approximately 7 years (the duration of each ISA will vary and be specified on the ISA records)

Conditions

Myasthenia Gravis
MG
gMG
Generalized Myasthenia Gravis
Generalized Myasthenia Gravis (gMG)
AChR-Ab Seropositive Generalized Myasthenia Gravis

Explore related trials

Myasthenia Gravis

Where it's being run

30 sites across 21 states
Florida3
Germany3
Texas2
Greece2
Lombardy2
Italy2
Japan2
California1

Who to contact

Sabine Coppieters, MD
[email protected]
857-350-4834
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Is at least 18 years of age and the local legal age of consent for clinical studies
Has been diagnosed with MG with consistent clinical features per the investigator's clinical judgment
If receiving MG therapy, including nonsteroidal immunosuppressive drugs (NSIDs), corticosteroids, or acetylcholinesterase (AChE) inhibitors either in combination or alone, the participant should receive a stable dosage before master protocol screening

Exclusion

Known autoimmune disease or any medical condition other than the indication under study that would interfere with an accurate assessment of clinical symptoms of MG or puts the participant at undue risk
Is MGFA (Myasthenia Gravis Foundation of America) Class V

What this trial measures

  • To determine the safety and tolerability of multiple regimens (monotherapy or add-on therapy to backbone therapy) in MG subtypesUp to approximately 7 years (the duration of each ISA will vary and be specified on the ISA records)